On the stock market since 2019, it operates in the world of health and science. It has 1,200 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price is looking for direction — no strong breakout, no collapse.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 15% a year on average.
Sales run at $172.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 79 buys and 31 sells. Management buying with its own money is usually read as a good sign.
A loss of $5.9M against $172.2M in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 18/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 34/100.
On our five-subject report card, STRRP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: STRRP is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.